1	2	3	4	5
5	M/s. Franco Indian Pharmaceuticals.	14- 02	0-43	13-59
6	M/s. Pfizer Ltd.		19-90	67-71
7	M/s. Anil Starch Products	11-61	Nil	*11. 61*
8			Nil	205-36
9	M/s. Tamilnadu Dadha Pharmaceuticals.	37- 97	Nil	37-97
10	M/s. Merind Ltd.. . .		Nil	781-58
11	M/s. Glaxo Labs	. 7178-18	819-00	6359-13
		11560-52	1306- 62	10253-90

Fixation of Prices of Bulk Drugs and their Formulation

657. SHRI MOHD. KHALEELUR RAHAMAN: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 402 given in the Rajya Sabha on the 31st December, 1990 and state:

(a) whether it is a fact that there are certain drugs which are imported as well as indigenously produced;

(b) what are he names of these drugs and on what basis their formulation are fixed;

(c) what is the indigenous price and landed cost of import of each;

(d) whether it is a fact that for mulations based on Sulphamoxole, Zinc Bacitiracin Ethisterone Novgestrol, Polymixio 'B' Sulphate and Thioridazine are being sold at very-high prices;

(e) what is the bulk drug price taken for fixation of the formulation prices; and

(f) by when the prices of bulk drugs would be fixed?

THE MINISTER OF PETROLEUM. AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) Yes, Sir.

(b> and (c) The requisite information to the extent available would be collected and will be laid on the Table of the House.

(d) All these bulk drugs have been brought under price control under Category II of DPCO, 1987. The prices of 'formulations based on Sulphamaxolle, Zinc Bactitracin, Polymixin 'B' Sulphate and Thioridazine have already been fixed in accordance with the provisions contained in the DPCO, 1987. BICP has been requested to workout the prices of formulations based on Ethisterone and Novgestrol on *suo moto* basis.

(e) The requisite information is as under: —

S. No.	Name of the Product		Price taken
			430- 00 per kg.
2	Zinc Bacitractin... . .	. Rs.	203- 10 per MU
3	Polymixin 'B' Sulphate ■.....	. Rs.	13-72 per MU
			6922-08 per kg.

(f) BICP is already on the job.

Justification for Allowing Incidentals to Fixation of Formulation Prices

658. SHRI MOHD. KHALEELUR RAHMAN: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 1168 given in Rajya Sabha on 7th January, 1991 and state:

(a) what are the names of two or three formulators for whom ceiling prices were announced in respect of Pilocarpine, Prednisolone and Trimethoprim plus Sulphadizine;

(b) whether it is a fast that drug industry is siphoning off its profits by giving discounts, incentives and distribution of gifts;

(c) what *were.* the expenses *on* this *account* of five major companies during the last one year; and

(d) what is the justification for allowing 20 per cent discounts over and above the trade commission and also allowing 8 per cent incidentals?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) The requisite information to the extent available is given in the annexed statement.

(b) to (d) While fixing the prices of controlled formulations, a fixed Maximum Allowable Post-Manufacturing Expenses (MAP£'., which is 75 per cent and 100 per cent in the case of Category I and Category II formulations respectively, is allowed. The manufacturers are required to meet their expenses including giving discounts, incentive, etc within the given MAPE. Incil plats within a limit of 8 per cent are allowed to cover Sales Tax, Octroi, Insurance, Freight etc

Statement

Sl. No.	Name of the bulk drug	Name of the formulator
		(1) Fair-deal Corporation (2) Bell Labs.
2	Prednisolone....	. (1) Wyeth Labs. (2) Hoechst
3	Trimethoprim + Sulphadizaine •	(3) Pifzer . (1) Hindustan Ciba Geigy (2) Astra IDL (3) Etinor